Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
Back

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

Not Recruiting

Open to: ALL

Age: 18.0 - N/A

Wolverhampton Dundee London Edinburgh London Torquay Middlesborough Belfast Truro Bristol Poole

Medical Conditions

Lung Neoplasms
Carcinoma, Non-Small-Cell Lung

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


This is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab (IPH2201) in adults with locally advanced (Stage III), unresectable NSCLC, who have not progressed following platinum-based cCRT.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Feb 2022 Jun 2026

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Durvalumab IV (intravenous infusion)

Intervention Arm Group : Arm A: Durvalumab and Oleclumab;Arm B: Durvalumab and Monalizumab;Arm C: Durvalumab and Placebo;

Intervention Type : DRUG
Intervention Description : Oleclumab IV (intravenous infusion)

Intervention Arm Group : Arm A: Durvalumab and Oleclumab;

Intervention Type : DRUG
Intervention Description : Monalizumab IV (intravenous infusion)

Intervention Arm Group : Arm B: Durvalumab and Monalizumab;

Intervention Type : OTHER
Intervention Description : Placebo IV (intravenous infusion)

Intervention Arm Group : Arm B: Durvalumab and Monalizumab;Arm C: Durvalumab and Placebo;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Research Site
    Wolverhampton
    WV10 OQP
  • Research Site
    Dundee
    DD1 9SY
  • Research Site
    London
    NW1 2PG
  • Research Site
    Edinburgh
    EH4 2XR
  • Research Site
    London
    W6 8RF
  • Research Site
    Torquay
    TQ2 7AA
  • Research Site
    Middlesborough
    TS4 3BW
  • Research Site
    Belfast
    BT9 7AB
  • Research Site
    Truro
    TR1 3LJ
  • Research Site
    Bristol
    BS2 8ED
  • Research Site
    Poole
    BH15 2JB


The study is sponsored by AstraZeneca



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT05221840
Last updated 22 July 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top